Healthcare / Medical DevicesKuala Lumpur
$0.32
+0.01 (+5.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-2.2M · quality 46.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$118M
P/E
15.8x
↓EV/EBITDA
7.7x
↓ROE
10.2%
↑Gross Margin
46.0%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.4%
FCF CAGR
-25.1%
FCF margin
6.5%
FCF / Net income
0.39x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $48.6M · net income $8.1M · FCF $3.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $48.6M | $48.6M | $54.6M | $45.4M | $50.7M |
| Net Income | $8.1M | $8.1M | $9.0M | $10.3M | $6.4M |
| EBITDA | $13.8M | $13.8M | $15.2M | $15.3M | $11.0M |
| EPS | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 |
| Gross Margin | 46.0% | 46.0% | 41.5% | 41.7% | 36.8% |
| Operating Margin | 19.9% | 19.9% | 20.6% | 24.8% | 17.0% |
| Net Margin | 16.7% | 16.7% | 16.5% | 22.7% | 12.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.06 | 0.15 |
| Current Ratio | 5.92 | 5.92 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $3.1M | $3.1M | $-2.2M | $-3.5M | $7.5M |
| Returns | |||||
| ROE | 10.2% | 10.2% | 12.5% | 16.4% | 12.2% |
| Valuation | |||||
| P/E | 15.75 | 15.75 | — | — | — |
| EV/EBITDA | 7.67 | 7.67 | — | — | — |
| P/B | 1.47 | 1.47 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | -11.0% | -11.0% | 20.1% | -10.5% | — |
| EPS Growth | -9.2% | -9.2% | -13.0% | 0.7% | — |
| Dividend Yield | 1.9% | 1.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
8.6%
EPS terminal req.
$0.03
Spread vs growth
-17.8%
5Y implied EPS CAGR
9.2%
EPS terminal req.
$0.03
Spread vs growth
-18.3%
10Y implied EPS CAGR
9.6%
EPS terminal req.
$0.05
Spread vs growth
-18.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.1%
Start / end P/E
17.5x → 14.4x
EPS bridge
0.02 → 0.02
Residual
+1.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.